
American Airlines Group Inc. starts Monday amid fresh safety concerns. The company’s stock shed around $672 million in market capitalization last week.
THURSDAY
Walmart's U.S. comparable-sales miss raised concern about consumer trade-offs. Costco fell 2.45% on the group's busiest session.
FRIDAY
Buyers reclaimed about $6.3 billion of estimated value. The bounce did not erase the week's 1.39% decline.
Costco's 6.9% adjusted U.S. July comp remains well above Walmart's latest 2.6% quarterly pace. The stock's premium rests on that consistency.
Risk: expensive shares leave little room for slower traffic or renewals. Fuel inflation also pressures shoppers and freight.
| Reference | Level | Gap |
|---|---|---|
| 50-day average | $74.52 | +6.8% |
| 200-day average | $88.42 | −10.0% |
| 52-week high | $126.71 | −37.2% |
| 52-week low | $65.08 | +22.3% |
| Metric | Reading |
|---|---|
| Trailing P/E | 25.1× |
| Forward P/E | 23.0× |
| Trailing FCF | $11.15B |
| FCF margin | 23.1% |
| 2026 revenue guide | $51.0B–$51.4B |
| Blood Sacrifice | 5 episodes |
| Global launch | Aug. 20 |
| H1 Netflix viewing | >97B hours |
| Next checkpoint | Weekly Top 10 rank and staying power |
A country-level or global Top 10 debut would confirm discovery. Persistence would matter more. A short-lived UK ranking would not justify a revenue revision on its own.
| Target | Value | Vs. $344.82 |
|---|---|---|
| Consensus average | $428.04 | +24.13% |
| Low | $340 | −1.40% |
| High | $515 | +49.35% |
| Revenue test | Value |
|---|---|
| Q1 FY27 actual | $81.62B |
| Q2 guide midpoint | $91.00B |
| Q2 consensus | $92.16B |
| Street premium to guide | +1.27% |
| Expected adjusted EPS | $2.09 |
| Firm | Rating | Target | Upside |
|---|---|---|---|
| BMO Capital | Outperform | $340 | 58% |
| Benchmark | Buy | $335 | 56% |
| Oppenheimer | Buy | $265 | 23% |
| Consensus | Strong Buy | $304.73 | 42% |
| Metric | 2026 | Comparison |
|---|---|---|
| Cash & securities | $237.9m | −$80.2m in H1 |
| Q2 operating expense | $42.9m | +55.0% YoY |
| Q2 net loss | $40.7m | +57.2% YoY |
| Runway at H1 loss pace | ~19 months | Preliminary |
| Firm | Action | Rating | Target | Versus $6.29 |
|---|---|---|---|---|
| Cantor Fitzgerald | Upgrade | Buy | $28 | +345% |
| Piper Sandler | Maintain | Hold | $2 | −68% |
| B. Riley | Maintain | Hold | $5 | −21% |
| Consensus | — | Hold | $10.50 avg. | +67% |
| Median | — | — | $6 | −5% |
Digital software, add-ons and network services: ¥693.8bn, or 74.0% of Q1 gaming sales.
| Measure | Q1 FY25 | Q1 FY26 | Change |
|---|---|---|---|
| Gaming sales | ¥936.5bn | ¥937.1bn | +0.1% |
| Operating income | ¥148.0bn | ¥202.0bn | +36.5% |
| Operating margin | 15.8% | 21.6% | +5.8 pts |
| Monthly active users | 123m | 125m | +1.6% |
| PS5 units | 2.5m | 1.6m | −36.0% |
| Firm | Call | Target | Upside |
|---|---|---|---|
| JPMorgan | Buy | ¥5,800 | +53.2% |
| Nomura | Buy | ¥4,900 | +29.5% |
| Benchmark | Buy | ¥4,200 | +11.0% |
| Bernstein | Hold | ¥3,800 | +0.4% |
| Citi | Hold | ¥3,500 | −7.5% |
Tokyo close: ¥3,785 on Aug. 21, 2026.
Sources: Sony Group Q1 FY2026 presentation and supplemental information; PlayStation Blog; campaign organizers; MarketWatch; AP; Yahoo Japan; Investing.com. The boycott sensitivity discussed in the accompanying article is illustrative, not a forecast. Price data are time-stamped above.
Down 3% year on year. Recurrent consumer spending was 84% of bookings. GAAP revenue rose 2% to $1.53bn.
The company also guides to GAAP revenue of $7.9bn–$8.1bn and capital spending near $290m.
Further leaks, a weak reveal, cancellations, launch slippage or soft mobile bookings could challenge the bullish target range.
The $120.8B senior preferred stated value does not count as regulatory capital. That is why large accounting equity does not translate directly into distributable value for common holders.
| Target | Price | Move from close |
|---|---|---|
| Low | $215 | -30.5% |
| Average | $326.34 | +5.5% |
| Median | $335 | +8.3% |
| High | $400 | +29.3% |
| What to watch | Verified baseline | Bull case | Risk |
|---|---|---|---|
| September product event | First-half September timing is reported, not official | Pro-first mix lifts average price | Delay or weaker premium demand |
| iPhone momentum | Q3 revenue +21.7% year over year | Upgrade cycle extends | Lower-priced models arrive later |
| Gross margin | 50.1%; about 2 points from tariff refunds | Mix offsets component costs | Underlying margin nearer 48.1% by simple subtraction |
| Street valuation | $326.34 average target | High target reaches $400 | Low target is $215 |
Market data: August 21, 2026, 4:00 p.m. EDT · U.S. market closed
Preliminary calculation from the August 18 high, August 20 low and Friday close. Price movement has multiple causes.
| Event | Date |
|---|---|
| Reported subpoenas filed | Aug. 20 |
| Official GTA VI extended look | Aug. 27 |
| Requested subpoena response | Sept. 4 |
| GTA VI launch | Nov. 19 |
The August 27 stream starts at 3 p.m. EDT on Netflix and 9 p.m. EDT on Rockstar channels.
| Measure | Value | Gap |
|---|---|---|
| Company low | $8.0bn | −9.7% |
| Company midpoint | $8.1bn | −8.6% |
| Company high | $8.2bn | −7.4% |
| Street estimate cited by Reuters | $8.86bn | Reference |
Guidance is unchanged despite unusually strong preorder demand.
| Firm | View | Target | Upside |
|---|---|---|---|
| BTIG | Buy | $313 | 30.6% |
| J.P. Morgan | Buy | $310 | 29.4% |
| Roth Capital | Buy | $300 | 25.2% |
| Wolfe Research | Buy | $289 | 20.6% |
| 28-analyst average | Strong Buy | $286.89 | 19.7% |
Risks: Rockstar has not fully authenticated the leaked material. Legal outcomes remain uncertain. GTA VI could face delays, weak preorder conversion, higher launch costs or softer engagement. Market-value estimates use an implied share count.
| Reference | Amount | ATM multiple |
|---|---|---|
| Cash + restricted cash | $508.8M | 1.18× |
| Q3 revenue midpoint | $272.5M | 2.20× |
| H1 capex | $335.1M | 1.79× |
| H1 investing cash use | $633.7M | 0.95× |
| Q2 actual | $191.9M |
| Q3 low | $255.0M |
| Q3 midpoint | $272.5M |
| Q3 high | $290.0M |
| Sale price | New shares | Dilution |
|---|---|---|
| $129.10 | 4.65M | 5.47% |
| $124.82 | 4.81M | 5.66% |
| $112.56 | 5.33M | 6.28% |
| Low target | $109 |
| Average | $163.40 |
| Median | $178 |
| High | $220 |
Market data: August 21, 2026, 4:00 p.m. EDT · U.S. market closed
The capped-ratio result is 2.16× the old model and equals 21.9% of Critical Metals’ June share count.
| Scheme VWAP | Ratio | Net shares |
|---|---|---|
| $8 or below | 0.045 | +32.1m |
| $12 | 0.035 | +14.9m |
| $16 or above | 0.025 | −2.4m |
The final ratio uses the specified 20-day VWAP, not one closing price.
| Firm | View | Target | Upside |
|---|---|---|---|
| Freedom Broker | Hold | $8 | 12.5% |
| Cantor Fitzgerald | Speculative Buy | $18 | 153.2% |
| Two-analyst average | Hold | $13 | 82.8% |
Targets are the latest available and may lag changing deal terms.
Risks: This is a preliminary quoted-share model. Options, performance rights, warrants and later capital changes are excluded. Completion still requires shareholder, option-holder and court approvals. Tanbreez also faces permitting, construction, financing, metallurgy and commodity-price risk.
Friday's rally followed the second box. Three consequential stages still remain.
SELLAS' rally now rests on an event-driven Phase 3 survival readout. Cash is meaningful, but it explains only 4.4% of market value.
SLS gained 54.4% across three consecutive winning weeks.
What Friday's equity value represents
No product revenue was reported for the first half of 2026.
REGAL is event-driven; the date cannot be fixed.
Statistically significant, clinically meaningful survival could support a potential BLA filing.
A missed survival endpoint would remove the main late-stage pillar beneath valuation.
Six months ended June 30, 2026
Weekly stock moves use August 14–21 closes. Targets are current S&P Global consensus data.
| Company | Weekly move | Consensus | Analysts | Average target | Implied return |
|---|---|---|---|---|---|
| Moderna · NASDAQ:MRNA | +129.2% | Hold | 23 | $91.39 | -37.0% |
| SELLAS · NASDAQ:SLS | +21.0% | Buy | 2 | $32.50 | +110.2% |
| Merck · NYSE:MRK | +12.3% | Buy | 28 | $147.77 | -3.1% |
| ImmunityBio · NASDAQ:IBRX | +2.9% | Strong Buy | 4 | $12.75 | +63.7% |
REGAL could miss its survival endpoint or face regulatory demands for more evidence. SLS009 remains early. Warrant exercises and future equity sales can dilute holders. A reversal in cancer-vaccine sentiment could erase gains before company-specific data arrive.
Stock data: August 21, 2026, 4:00 p.m. EDT. Dashboard status: August 22, 2026, 6:24 a.m. EDT. Sources: SELLAS SEC filings; ClinicalTrials.gov; Yahoo Finance; StockAnalysis. Peer programs differ in platform, indication and stage.
| Firm | View | Target |
|---|---|---|
| Benchmark | Buy | $45 |
| Northland | Buy | $45 |
| Cantor Fitzgerald | Overweight | $40 |
| Canaccord | Buy | $32 |
| Roth MKM | Buy | $30 |
| Q2 metric | 2026 | YoY |
|---|---|---|
| Revenue | $108.5M | +89% |
| Adjusted EBITDA | $28.5M | +$41.0M |
| NdPr production | 840 MT | +41% |
| NdPr sales | 1,006 MT | +127% |
| REO production | 11,072 MT | -16% |
| Measure | Value | Vs. close |
|---|---|---|
| Low target | $58.00 | -3.4% |
| Average target | $75.38 | +25.5% |
| Median target | $75.00 | +24.9% |
| High target | $100.00 | +66.5% |
| Consensus | Strong Buy | 18 analysts |
Friday's 9.14% rebound left MP only 2.26% higher for the week. The operating case is improving, but the earnings bridge remains policy-sensitive: Q2 price-protection income equaled nearly two-thirds of adjusted EBITDA.
Rare-earth trade policy
Independence magnet qualification
10X construction progress
Follow-through after high-volume rally
Sources: Nasdaq market data; MP Materials Q2 2026 results; S&P Global analyst data via StockAnalysis, last updated August 19, 2026. Adjusted EBITDA is non-GAAP. Percentages are calculated from reported figures and may vary slightly due to rounding.
Moderna · NASDAQ:MRNA
Day range $132.42–$159.47 · Volume 86.74M vs. 15.08M average
$62.96 before the readout to $145.13 Friday.
$82.17 per share × 399.24M shares.
About 8.4× June cash and investments.
Before the $950M litigation payment made in July.
INTerpath-001 enrolled 1,137 melanoma patients and met recurrence-free and distant-metastasis-free survival endpoints. No new safety signal emerged. The full Phase 3 hazard ratios, confidence intervals, subgroup results and overall-survival data remain undisclosed. Investors have added $32.81 billion of equity value without the effect size.
Risk: the price can reverse if detailed efficacy, safety or regulatory timing falls short of the expectations embedded in the rally.
Sources: Google Finance · Phase 3 release · SEC Q2 filing
Headline book value does not flow cleanly to common shareholders.
| Measure | Q2 2026 | Q1 2026 |
|---|---|---|
| Net income | $4.0B | $3.7B |
| Net revenue | $7.6B | $7.3B |
| Credit-loss provision | $485M | $277M |
| Non-interest expense | $2.1B | $2.2B |
| Net worth | $116.5B | $112.5B |
| Firm | View | Target |
|---|---|---|
| B. Riley | Neutral | $7.00 |
| Wedbush | Neutral | $8.00 |
| KBW | Underperform | $8.50 |
| BTIG | Buy | $20.00 |
| 7-analyst aggregate | Hold | $12.25 |
Today’s highest-ranked model selections.